Acceleron pharma inc (XLRN)

CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Operating Activities
Net loss

-137,744

-124,858

-136,018

-119,628

-130,705

-118,871

-112,064

-108,535

-109,266

-108,454

-99,815

-95,133

-87,482

-57,014

-64,807

-55,895

-44,259

-63,894

-54,429

-50,544

-56,713

-51,259

-51,752

-62,293

-32,665

-21,898

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

3,963

3,900

3,764

3,776

3,729

3,700

3,645

3,442

3,163

2,800

2,541

2,185

1,893

1,676

1,463

1,317

1,209

1,176

1,157

1,150

1,144

1,118

1,066

1,008

956

915

0

0

0

Loss on disposition of fixed assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-37

-39

-25

0

0

0

-

-

-

-

Stock-based compensation

22,682

22,995

23,817

24,918

25,865

24,569

24,433

23,731

27,361

28,248

27,047

25,929

20,892

18,557

17,167

15,644

13,751

12,075

9,746

7,877

6,332

4,778

4,082

3,380

2,786

2,196

0

0

0

Accretion of deferred interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-536

-451

-365

-280

342

0

0

0

Amortization of deferred debt issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

36

40

45

204

186

0

0

0

Change in fair value of warrants

-

-

-

-

-

-

-

-

-

-

-1,553

-1,171

1,466

-7,262

4,097

688

-4,733

3,528

-2,508

-3,286

-1,469

-5,037

6,102

20,645

21,818

26,875

0

0

0

Net amortization of premium on investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

777

1,041

0

0

0

0

-

-

-

-

Other non-cash items

-534

-128

750

-4

-1,280

-409

-2,041

-1,832

-1,168

-1,168

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on retirement of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

76

0

0

0

Changes in assets and liabilities:
Prepaid expenses and other assets

1,364

2,429

4,091

2,439

2,474

2,986

3,727

4,412

1,202

675

-226

110

934

1,411

1,105

1,260

526

-7

-1,369

-349

960

255

1,784

817

12

823

0

0

0

Collaboration receivables (all amounts are with a related party)

5,655

1,508

3,618

1,779

-451

3,470

379

788

-338

336

-140

-358

513

-394

-931

-2,047

-992

261

722

1,555

1,416

-249

-875

-609

-366

840

0

0

0

Non-cash lease expense

5,286

5,143

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Related party receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4

0

0

0

Accounts payable

44

1,876

682

2,273

2,202

-673

142

-392

865

-504

-1,118

1,024

-92

644

-576

-1,224

-734

151

-667

-824

-728

-161

2,133

1,362

1,604

-53

0

0

0

Accrued expenses

3,654

6,258

8,899

2,300

1,593

1,904

-530

1,538

-789

1,493

295

-1,136

-1,556

524

3,328

3,078

5,269

4,976

2,943

1,774

2,097

-17

1,388

2,297

-825

709

0

0

0

Operating lease obligations

5,482

5,333

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other changes in operating assets and liabilities

0

17

-97

-268

-512

-665

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-542

-541

-542

-549

-590

-661

-957

-1,184

-1,379

-1,455

-1,370

-1,673

-2,207

-2,564

-25,107

-26,949

0

0

0

Deferred rent

-

-

-

-

-

-

-

-

-

-

24

-499

-566

96

967

1,047

867

519

-229

5

499

499

500

499

499

499

0

0

0

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

150

94

93

-106

0

0

0

-

-

-

-

-

-

-

-

Net cash used in operating activities

-114,041

-93,804

-106,581

-89,632

-97,583

-94,706

-86,480

-83,202

-78,212

-76,544

-72,332

-68,536

-67,247

-44,545

-40,416

-36,371

-29,447

-44,211

-45,369

-52,748

-54,573

-53,220

-40,965

-32,148

-31,387

-19,650

0

0

0

Investing Activities
Purchases of investments

189,476

395,138

379,096

301,370

253,739

73,570

253,260

245,873

215,661

179,935

85,994

57,691

93,011

218,314

132,934

162,786

136,005

134,697

134,328

132,709

124,216

0

0

0

0

-

-

-

-

Proceeds from sales and maturities of investments

351,362

327,134

288,714

217,741

238,690

199,087

172,595

155,291

110,962

119,965

177,770

118,932

127,326

112,889

17,667

55,878

45,781

26,685

0

0

0

-

-

-

-

-

-

-

-

Purchases of property and equipment

3,126

3,287

2,855

2,490

2,673

2,590

2,658

2,841

4,223

4,396

4,773

4,748

3,568

3,380

2,546

2,275

1,290

959

675

379

522

514

618

561

377

307

0

0

0

Net cash provided by (used in) investing activities

158,760

-71,291

-93,237

-86,119

-17,722

122,927

-83,323

-93,423

-108,922

-64,366

87,003

56,493

30,747

-108,805

-117,813

-109,183

-91,514

-108,971

-104,865

-118,103

-124,738

-514

-618

-561

-377

-307

0

0

0

Financing Activities
Payments made to repurchase redeemable convertible preferred stock, common stock and warrants to purchase common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

300

0

0

0

Proceeds from issuance of common stock from public offering, net of issuance costs

-25

248,130

248,130

248,130

248,155

0

0

0

0

-

-

-

-

140,697

140,650

140,344

140,713

-47

0

0

0

-

-

-

-

-

-

-

-

Payments for withholding taxes on restricted stock units

-

-

-

-

-

-

-

-

-

-

226

140

140

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock from public offering, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Proceeds from issuance of common stock from private placements

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Payments of long-term debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

16,331

0

0

0

-

-

-

-

Proceeds from issuances of common stock related to employee stock purchase plan

-

-

-

-

-

-

-

-

-

-

827

784

784

658

657

666

666

589

0

0

0

-

-

-

-

-

-

-

-

Payments for capital lease expenditures

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options and warrants to purchase common stock

-

-

-

-

-

-

-

-

-

-

5,021

5,160

5,731

5,312

4,500

3,383

3,449

3,963

3,826

4,441

4,674

4,188

3,952

2,504

1,399

653

0

0

0

Payments for capital lease expenditures

-

-

-

-

-

139

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from exercises and vesting of stock awards, ESPP contributions, and exercise of warrants to purchase common stock

18,302

10,590

8,864

12,164

12,430

16,285

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

18,277

258,720

256,933

260,233

260,524

16,146

43,736

225,491

223,713

220,296

193,608

6,110

6,312

146,667

145,807

144,393

144,828

4,505

4,416

4,757

4,990

117,031

114,360

208,494

207,389

93,509

0

0

0

Net increase in cash, cash equivalents and restricted cash

62,996

93,625

57,115

84,482

145,219

44,367

-126,067

48,866

36,579

79,386

208,279

-5,933

-30,188

-6,683

-12,422

-1,161

23,867

-148,677

-145,818

-166,094

-174,321

63,297

72,777

175,785

175,625

73,552

0

0

0

Supplemental Disclosure of Cash Flow Information:
Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,574

1,969

2,381

2,796

1,657

0

0

0

Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Accretion of dividends, interest, redemption value, and issuance costs on preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

19,870

0

0

0

Capitalized follow-on public offering costs included in accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

0

0

-

-

-

-

Purchase of property and equipment included in accounts payable and accrued expenses

0

-

-

-

0

-

-

-

-1,261

194

767

444

1,713

397

213

371

715

270

86

129

-64

11

0

0

0

-

-

-

-

Reclassification of warrant liability to additional paid-in capital

-

-

-

-

-

-

-

-

0

-

0

0

0

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

Acquisition of capital lease

-

-

-

-

-

-

-

-

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-